Incidence and risk of xerosis with targeted anticancer therapies - 14/03/15
Abstract |
Background |
Many targeted therapies used in the treatment of cancer can lead to the development of xerosis, but the incidence and relative risk of xerosis have not been ascertained.
Objective |
We conducted a systematic review and metaanalysis of clinical trials, to ascertain the incidence and risk of developing xerosis after taking anticancer drugs.
Methods |
The PubMed (1966-October 2013), Web of Science (January 1998-October 2013), and American Society of Clinical Oncology abstracts (2004-2013) databases were searched for clinical trials of 58 targeted agents. Results were calculated using random or fixed effects models.
Results |
The incidences of all- and high-grade xerosis were 17.9% (95% confidence interval [CI]: 15.6-20.4%) and 1.0% (95% CI: 0.9-1.5%), respectively. The risk of developing all-grade xerosis was 2.99 (95% CI: 2.0-4.3), and it varied across different drugs (P < .001).
Limitations |
The reporting of xerosis may vary among clinicians and institutions, and the incidence may be affected by age, concomitant medications, comorbidities, and underlying malignancies or skin conditions.
Conclusion |
Patients receiving targeted therapies have a significant risk of developing xerosis. Patients should be counseled and treated early for this symptom to prevent suboptimal dosing and quality of life impairment.
Le texte complet de cet article est disponible en PDF.Key words : Bcr-Abl, CD20, CD52, dry skin, EGFR, HDAC, HER2, incidence, MEK, mTOR, Raf, risk, xerosis, VEGFR
Abbreviations used : ADL, AE, CI, CTCAE, dAE, EGFR, EGFRI, MEK, mTOR, QoL, RR, VEGF, VEGFR
Plan
Supported by the Memorial Sloan Kettering Cancer Center. |
|
Ms Ciccolini is a speaker for Amgen. Dr Wu is a speaker, consultant, or advisor for Bayer-Onyx, Dendeon, Medivation, Novartis, and Pfizer. Dr Lacouture is a speaker, consultant, or advisor for Advancell, Amgen, AstraZeneca, Augmentium, Aveo, Bayer, Berg Pharma, Biopharm Communications, Boehringer Ingelheim, Brickell Biotech, Bristol-Myers Squibb, Clinical Assistance Programs, Clinical Care Options, EMD Serono, Envision Communications, Foamix, Galderma, Genentech, GlaxoSmithKline, Helsinn, Institute for Medical Education and Research, Integro-MC, Lindi Skin, Medscape, Medtrend International, Merck, Nerre Therapeutics, Novartis, Novocure, Oncology Specialty Group, OSI Pharmaceuticals, Permanyer, Physicians Education Resource, Pierre Fabre, Pfizer, Reata Pharmaceuticals, Roche, Sandoz, Sanofi Aventis, and Threshold Pharmaceuticals. The remaining authors have conflicts of interest to declare. |
|
The views expressed in this article are those of the authors and do not reflect the official policy or position of the Department of the Navy, Department of Defense, or the US government. Dr Valentine is a military service member, and this work was prepared as part of her official duty. |
Vol 72 - N° 4
P. 656-667 - avril 2015 Retour au numéroBienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?